ESMO 2026

Oncology

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

News

Hutchmed, AZ file Orpathys for lung cancer on ESMO data

Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.

Oncology

Global oncology innovation from Hengrui Pharma

Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.

News

ESMO26: Ris-rez offers hope of osteosarcoma breakthrough

There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.

Oncology

ESMO26: Taiho Oncology on improving the lives of patients wi...

Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.

News

ESMO26: AZ's claudin ADC doubles survival in GI cancers

AstraZeneca's CLARITY-Gastric01 trial of sone-ve in CLDN18.2-positive gastrointestinal cancers reveals a 53% reduction in the risk of death.

On the benefits of earlier oncological intervention, with Jo...

Hutchmed, AZ file Orpathys for lung cancer on ESMO data

Global oncology innovation from Hengrui Pharma

ESMO26: Ris-rez offers hope of osteosarcoma breakthrough

ESMO26: Taiho Oncology on improving the lives of patients wi...

ESMO26: AZ's claudin ADC doubles survival in GI cancers

BMS shakes up R&D under CMO Cristian Massacesi

Securing your ROI: Turning post-acquisition integration into...

ESMO 2026

Editor's Picks